<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7362854\results\search\drug\results.xml">
  <result pre="incomparable with the danger of the disease. However, remdesivir (1)," exact="lopinavir" post="(2) and ritonavir (3), favipiravir (4), chloroquine (5) and"/>
  <result pre="danger of the disease. However, remdesivir (1), lopinavir (2) and" exact="ritonavir" post="(3), favipiravir (4), chloroquine (5) and hydroxychloroquine (6) (Fig.Â"/>
  <result pre="However, remdesivir (1), lopinavir (2) and ritonavir (3), favipiravir (4)," exact="chloroquine" post="(5) and hydroxychloroquine (6) (Fig.Â 1 A) and their"/>
  <result pre="lopinavir (2) and ritonavir (3), favipiravir (4), chloroquine (5) and" exact="hydroxychloroquine" post="(6) (Fig.Â 1 A) and their combinations [[45], [46],"/>
  <result pre="it is administrated only intravenously [[49], [50], [51]]. Anti-HIV drug" exact="lopinavir" post="is developed from ritonavir. Both are created against HIV-1"/>
  <result pre="2014 for treating viral strains unresponsive to current antivirals [54,55]." exact="Chloroquine" post="(ResochinÂ®, AralenÂ®) and hydroxychloroquine (DolquineÂ®, PlaquenilÂ®, AxemalÂ®) are antimalarial"/>
  <result pre="strains unresponsive to current antivirals [54,55]. Chloroquine (ResochinÂ®, AralenÂ®) and" exact="hydroxychloroquine" post="(DolquineÂ®, PlaquenilÂ®, AxemalÂ®) are antimalarial drugs. The latter drug"/>
  <result pre="the following chemical entities of umifenovir 7, agent EIDD-2801 8," exact="ribavirin" post="9, ruxolitinib 10, ingavirin 11, azithromycin 12, ivermectin 13"/>
  <result pre="chemical entities of umifenovir 7, agent EIDD-2801 8, ribavirin 9," exact="ruxolitinib" post="10, ingavirin 11, azithromycin 12, ivermectin 13 and danoprevir"/>
  <result pre="7, agent EIDD-2801 8, ribavirin 9, ruxolitinib 10, ingavirin 11," exact="azithromycin" post="12, ivermectin 13 and danoprevir 14 (Fig.Â 1B) must"/>
  <result pre="EIDD-2801 8, ribavirin 9, ruxolitinib 10, ingavirin 11, azithromycin 12," exact="ivermectin" post="13 and danoprevir 14 (Fig.Â 1B) must be considered"/>
  <result pre="This drug candidate can be taken in pill form [62,63]." exact="Ribavirin" post="(RebetolÂ®, VirazoleÂ®, etc.) is a synthetic nucleoside antiviral drug,"/>
  <result pre="with a range of dosing regimens in different clinical settings." exact="Ribavirin" post="was found clinically effective against influenza, herpesvirus infections, hemorrhagic"/>
  <result pre="ineffective against Ebola and Marburg viruses [[64], [65], [66], [67]]." exact="Ruxolitinib" post="(AkaviÂ®) is approved in 2011 to treat certain rare"/>
  <result pre="metapneumoviruses, enteroviruses, including Coxsackie virus and rhinovirus [[70], [71], [72]]." exact="Azithromycin" post="(ZithromaxÂ®) is an inexpensive semisynthetic antibiotic drug used for"/>
  <result pre="as a drug in combination with ritonavir, peginterferon alfa and" exact="ribavirin" post="for the treatment of treatment-naive patients with non-cirrhotic genotype"/>
  <result pre="and 1,2,4-triazole 9), which resemble the respective RNA bases of" exact="adenosine" post="and cytidine, two are so-called peptide-heterocyclic chimera derivatives (comp."/>
  <result pre="the RO5, failing two or three criteria. The case of" exact="chloroquine" post="(5) is a border zone; although it has small"/>
  <result pre="of the immune system. mUN, unknown detailed anti-influenza virus mechanism;" exact="azithromycin" post="does not affect attachment of viruses onto the cell"/>
  <result pre="(less than 5) for Lipinskiâ€™s rule, excluding two drugs, i.e.," exact="lopinavir" post="(2) and ritonavir (3), which are highly lipophilic molecules"/>
  <result pre="for Lipinskiâ€™s rule, excluding two drugs, i.e., lopinavir (2) and" exact="ritonavir" post="(3), which are highly lipophilic molecules with respective cLogP"/>
  <result pre="and 7.14. In contrast, the drugs favipiravir (4), EIDD-2801 (8)," exact="ribavirin" post="(9), ruxolitinib (10) and ingavirin (11) are highly hydrophilic"/>
  <result pre="In contrast, the drugs favipiravir (4), EIDD-2801 (8), ribavirin (9)," exact="ruxolitinib" post="(10) and ingavirin (11) are highly hydrophilic molecules with"/>
  <result pre="proteins. Interestingly, three macrocyclic compounds displaying an appropriate lipophilicity, i.e.," exact="azithromycin" post="(12), ivermectin (13) and danoprevir (14), are less lipophilic"/>
  <result pre="three macrocyclic compounds displaying an appropriate lipophilicity, i.e., azithromycin (12)," exact="ivermectin" post="(13) and danoprevir (14), are less lipophilic than lopinavir"/>
  <result pre="(12), ivermectin (13) and danoprevir (14), are less lipophilic than" exact="lopinavir" post="(2) and ritonavir (3), which possess an alicyclic peptide"/>
  <result pre="and danoprevir (14), are less lipophilic than lopinavir (2) and" exact="ritonavir" post="(3), which possess an alicyclic peptide backbone. All of"/>
  <result pre="5 and 6, although they have almost identical molecular volumes," exact="hydroxychloroquine" post="is more polar, less lipophilic, and thus encounters more"/>
  <result pre="small nitrogen-containing molecule drugs such as favipiravir (4), umifenovir (7)," exact="ruxolitinib" post="(10) and ingavirin (11) also demonstrated good absorption (76â€&quot;90%),"/>
  <result pre="ring increases the TPSA parameter of nucleoside-based drugs EIDD-2801 (8)," exact="ribavirin" post="(9) and remdesivir (1) (TPSAÂ =Â 143.15â€&quot;203.57Â Ã…2). Increased"/>
  <result pre="Increased TPSA values are also observed for macrocyclic molecule drugs" exact="azithromycin" post="(12), ivermectin (13) and danoprevir (14). Among these three"/>
  <result pre="values are also observed for macrocyclic molecule drugs azithromycin (12)," exact="ivermectin" post="(13) and danoprevir (14). Among these three drugs, ivermectin"/>
  <result pre="(12), ivermectin (13) and danoprevir (14). Among these three drugs," exact="ivermectin" post="is the most hydrophilic molecule, is well resorbed after"/>
  <result pre="be transferred in the presence of efflux pumps, for which" exact="ivermectin" post="is a substrate [102]. In addition, these drugs have"/>
  <result pre="flexibility (ROTBÂ =Â 7â€&quot;8) according to the Veberâ€™s rule. Curiously," exact="chloroquine" post="(5) and hydroxychloroquine (6) show the same capacity, and"/>
  <result pre="7â€&quot;8) according to the Veberâ€™s rule. Curiously, chloroquine (5) and" exact="hydroxychloroquine" post="(6) show the same capacity, and remdesivir (1), lopinavir"/>
  <result pre="and hydroxychloroquine (6) show the same capacity, and remdesivir (1)," exact="lopinavir" post="(2) and ritonavir (3) are much more flexible molecules"/>
  <result pre="show the same capacity, and remdesivir (1), lopinavir (2) and" exact="ritonavir" post="(3) are much more flexible molecules (ROTBÂ =Â 15â€&quot;17)."/>
  <result pre="ABSÂ 1â€&quot;3, 8, 9, 13 and 14), except for the" exact="azithromycin" post="molecule, which exhibits a 8.63 value of pKa, and"/>
  <result pre="is noteworthy that as ACE2 inhibitors, two small drugs of" exact="chloroquine" post="(5) and hydroxychloroquine (6), with respective pKa values of"/>
  <result pre="as ACE2 inhibitors, two small drugs of chloroquine (5) and" exact="hydroxychloroquine" post="(6), with respective pKa values of 10.06 and 9.22,"/>
  <result pre="ChemDraw program do not supply a second ionization constant for" exact="chloroquine" post="and hydroxychloroquine. However, in practice, it was found that"/>
  <result pre="chloroquine and hydroxychloroquine. However, in practice, it was found that" exact="chloroquine" post="has two basic groups corresponding to the quinoline-ring nitrogen"/>
  <result pre="Moreover, at a physiologic pH of 7.4 (plasma), 18% of" exact="chloroquine" post="is monoprotonated but still soluble in lipid and able"/>
  <result pre="lysosome (pHÂ âˆ¼Â 4â€&quot;5), it is biprotonated [103,104]. In practice," exact="chloroquine" post="is administered as a phosphate salt, whereas hydroxychloroquine is"/>
  <result pre="In practice, chloroquine is administered as a phosphate salt, whereas" exact="hydroxychloroquine" post="is processed as a sulfate, and both drugs are"/>
  <result pre="5.24) and less soluble in water (LogSÂ =Â âˆ’6.04) than" exact="chloroquine" post="and hydroxychloroquine drugs (LogSÂ =Â âˆ’4.53 andÂ âˆ’3.77, respectively)"/>
  <result pre="less soluble in water (LogSÂ =Â âˆ’6.04) than chloroquine and" exact="hydroxychloroquine" post="drugs (LogSÂ =Â âˆ’4.53 andÂ âˆ’3.77, respectively) (TableÂ 1)."/>
  <result pre="different chemical natures and modes of action, i.e., umifenovir (7)," exact="azithromycin" post="(12) and ivermectin (13), that do not virtually alter"/>
  <result pre="and modes of action, i.e., umifenovir (7), azithromycin (12) and" exact="ivermectin" post="(13), that do not virtually alter any vital proteins,"/>
  <result pre="drugs that interact with one human target, i.e., remdesivir (1)," exact="lopinavir" post="(2), ritonavir (3) and danoprevir (14), which bind to"/>
  <result pre="interact with one human target, i.e., remdesivir (1), lopinavir (2)," exact="ritonavir" post="(3) and danoprevir (14), which bind to protease enzymes,"/>
  <result pre="treatment for COVID-19 in the USA (remdesivir) and Japan (favipiravir)." exact="Ruxolitinib" post="(10), an anticancer drug tested for its potential to"/>
  <result pre="recent work on control of the SARS-CoV-2 infection inÂ vitro," exact="hydroxychloroquine" post="was less toxic and more efficient as a viral"/>
  <result pre="less toxic and more efficient as a viral inhibitor than" exact="chloroquine" post="[106], which confirms the current in silico calculation, but"/>
  <result pre="of (hydroxy) chloroquine, offers a cautiously optimistic report that (hydroxy)" exact="chloroquine" post="might have a prophylactic and/or therapeutic effect against COVID-19"/>
  <result pre="[113]. Special attention has been focused on use of (hydroxy)" exact="chloroquine" post="drugs for a COVID-19 cure. Both drugs, which show"/>
  <result pre="T-cell stimulators and inflammatory molecules [114]. It is noteworthy that" exact="hydroxychloroquine" post="has been found to be a more potent SARS-CoV-2"/>
  <result pre="COVID-19 treatment in several countries. Recently, it was found that" exact="dexamethasone" post="(glucocorticoid) reduced deaths in hospitalized patients with severe COVID-19"/>
  <result pre="criterions of drug selection are still debatable. The story with" exact="hydroxychloroquine" post="tests is very meaningful [[146], [147], [148], [149]], itâ€™s"/>
  <result pre="open drug discovery for SARS-CoV-2, Drug DiscovToday Off.2552020928941 45GautretP.LagierJ.C.ParolaP.MeddebL.MailheM.DoudierB.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
  <result pre="rapid antiviral clearance or clinical benefit with the combination of" exact="hydroxychloroquine" post="and azithromycin in patients with severe COVID-19 infectionMed. Maladies"/>
  <result pre="clearance or clinical benefit with the combination of hydroxychloroquine and" exact="azithromycin" post="in patients with severe COVID-19 infectionMed. Maladies Infect.5042020384 47WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir"/>
  <result pre="in patients with severe COVID-19 infectionMed. Maladies Infect.5042020384 47WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) inÂ"/>
  <result pre="for old drugsCurr. Med. Chem.252420182797281028901270 57PlantoneD.KoudriavtsevaT.Current and future use of" exact="chloroquine" post="and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases:"/>
  <result pre="drugsCurr. Med. Chem.252420182797281028901270 57PlantoneD.KoudriavtsevaT.Current and future use of chloroquine and" exact="hydroxychloroquine" post="in infectious, immune, neoplastic, and neurological diseases: a mini-reviewClin."/>
  <result pre="neoplastic, and neurological diseases: a mini-reviewClin. Drug Invest.3882018653671 58TouretF.de LamballerieX.Of" exact="chloroquine" post="and COVID-19Antivir. Res.177202010476210.1016/j.antiviral.2020.104762 59YazdanyJ.KimA.H.J.Use of hydroxychloroquine and chloroquine during"/>
  <result pre="Drug Invest.3882018653671 58TouretF.de LamballerieX.Of chloroquine and COVID-19Antivir. Res.177202010476210.1016/j.antiviral.2020.104762 59YazdanyJ.KimA.H.J.Use of" exact="hydroxychloroquine" post="and chloroquine during the COVID-19 pandemic: what every clinician"/>
  <result pre="58TouretF.de LamballerieX.Of chloroquine and COVID-19Antivir. Res.177202010476210.1016/j.antiviral.2020.104762 59YazdanyJ.KimA.H.J.Use of hydroxychloroquine and" exact="chloroquine" post="during the COVID-19 pandemic: what every clinician should knowAnn."/>
  <result pre="poised for COVID-19 clinical trialsAvailable at:https://cen.acs.org/biological-chemistry/infectious-disease/Emory-discovered-antiviral-poised-COVID/98/i122020 64GraciJ.D.CameronC.E.Mechanisms of action of" exact="ribavirin" post="against distinct virusesRev. Med. Virol.1612006374816287208 65Loustaud-RattiV.RousseauA.MarquetP.DenisF.AlainS.Ribavirin in chronic hepatitis"/>
  <result pre="drug repurposing on the fast trackNat. Biotechnol.384202037939132205870 88RajeshkumarN.V.YabuuchiS.PaiS.G.MaitraA.HidalgoM.DangC.V.Fatal toxicity of" exact="chloroquine" post="or hydroxychloroquine with metformin in miceBioRxiv202010.1101/2020.03.31.018556 89FoucquierJ.GuedjM.Analysis of drug"/>
  <result pre="on the fast trackNat. Biotechnol.384202037939132205870 88RajeshkumarN.V.YabuuchiS.PaiS.G.MaitraA.HidalgoM.DangC.V.Fatal toxicity of chloroquine or" exact="hydroxychloroquine" post="with metformin in miceBioRxiv202010.1101/2020.03.31.018556 89FoucquierJ.GuedjM.Analysis of drug combinations: current"/>
  <result pre="fast trackNat. Biotechnol.384202037939132205870 88RajeshkumarN.V.YabuuchiS.PaiS.G.MaitraA.HidalgoM.DangC.V.Fatal toxicity of chloroquine or hydroxychloroquine with" exact="metformin" post="in miceBioRxiv202010.1101/2020.03.31.018556 89FoucquierJ.GuedjM.Analysis of drug combinations: current methodological landscapePharm."/>
  <result pre="molecular properties and bioactivity scoreAvailable at:http://www.Molinspiration.com2011 99FerrariV.CutlerD.J.Kinetics and thermodynamics of" exact="chloroquine" post="and hydroxychloroquine transport across the human erythrocyte membraneBiochem. Pharmacol.411199123301986742"/>
  <result pre="and bioactivity scoreAvailable at:http://www.Molinspiration.com2011 99FerrariV.CutlerD.J.Kinetics and thermodynamics of chloroquine and" exact="hydroxychloroquine" post="transport across the human erythrocyte membraneBiochem. Pharmacol.411199123301986742 100CaoY.C.DengQ.X.DaiS.X.Remdesivir for"/>
  <result pre="and pharmacodynamic considerations regarding efficacy and safetyMalar. J.161201716128434401 103BrowningD.J.BrowningD.J.Hydroxychloroquine and" exact="Chloroquine" post="Retinopathy in: Hydroxychloroquine and Chloroquine Retinopathy2014Springer Science+Business Media New"/>
  <result pre="regarding efficacy and safetyMalar. J.161201716128434401 103BrowningD.J.BrowningD.J.Hydroxychloroquine and Chloroquine Retinopathy in:" exact="Hydroxychloroquine" post="and Chloroquine Retinopathy2014Springer Science+Business Media New York3563 104TitusE.O.Recent developments"/>
  <result pre="and safetyMalar. J.161201716128434401 103BrowningD.J.BrowningD.J.Hydroxychloroquine and Chloroquine Retinopathy in: Hydroxychloroquine and" exact="Chloroquine" post="Retinopathy2014Springer Science+Business Media New York3563 104TitusE.O.Recent developments in the"/>
  <result pre="and mechanism of action of chloroquine, TherDrug Monit1141989369379 105TettS.E.CutlerD.J.DayR.O.BrownK.F.Bioavailability of" exact="hydroxychloroquine" post="tablets in healthy volunteers, BritJ.Â Clin. Pharm.2761989771779 106LiuJ.CaoR.XuM.WangX.ZhangH.HuH.Hydroxychloroquine, a"/>
  <result pre="inhibiting SARS-CoV-2 infection inÂ vitroCell Discov6120201610.1038/s41421-020-0156-032194981 107MarmorM.F.KellnerU.LaiT.Y.MellesR.B.MielerW.F.Recommendations on screening for" exact="chloroquine" post="and hydroxychloroquine retinopathy (2016 revision)Ophthalmol. Times1236201613861394 108VerbaanderdC.MaesH.SchaafM.B.SukhatmeV.P.PantziarkaP.SukhatmeV.Repurposing drugs in"/>
  <result pre="infection inÂ vitroCell Discov6120201610.1038/s41421-020-0156-032194981 107MarmorM.F.KellnerU.LaiT.Y.MellesR.B.MielerW.F.Recommendations on screening for chloroquine and" exact="hydroxychloroquine" post="retinopathy (2016 revision)Ophthalmol. Times1236201613861394 108VerbaanderdC.MaesH.SchaafM.B.SukhatmeV.P.PantziarkaP.SukhatmeV.Repurposing drugs in oncology (ReDO)-chloroquine"/>
  <result pre="retinopathy (2016 revision)Ophthalmol. Times1236201613861394 108VerbaanderdC.MaesH.SchaafM.B.SukhatmeV.P.PantziarkaP.SukhatmeV.Repurposing drugs in oncology (ReDO)-chloroquine and" exact="hydroxychloroquine" post="as anti-cancer agentsEcancermedicalscience11201778129225688 109McGreadyR.ThwaiK.L.ChoT.LooareesuwanS.WhiteN.J.NostenF.The effects of quinine and chloroquine"/>
  <result pre="oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agentsEcancermedicalscience11201778129225688 109McGreadyR.ThwaiK.L.ChoT.LooareesuwanS.WhiteN.J.NostenF.The effects of" exact="quinine" post="and chloroquine antimalarial treatments in the first trimester of"/>
  <result pre="and hydroxychloroquine as anti-cancer agentsEcancermedicalscience11201778129225688 109McGreadyR.ThwaiK.L.ChoT.LooareesuwanS.WhiteN.J.NostenF.The effects of quinine and" exact="chloroquine" post="antimalarial treatments in the first trimester of pregnancyTrans. R."/>
  <result pre="pregnancyTrans. R. Soc. Trop. Med. Hyg.962200218018412055810 110HuT.Y.FriemanM.WolframJ.Insights from nanomedicine into" exact="chloroquine" post="efficacy against COVID-19Nat. Nanotechnol.154202024724932203437 111CortegianiA.IngogliaG.IppolitoM.GiarratanoA.EinavS.AÂ systematic review on the"/>
  <result pre="Nanotechnol.154202024724932203437 111CortegianiA.IngogliaG.IppolitoM.GiarratanoA.EinavS.AÂ systematic review on the efficacy and safety of" exact="chloroquine" post="for the treatment of COVID-19J.Â Crit. Care202010.1016/j.jcrc.2020.03.005 112LianN.XieH.LinS.HuangJ.ZhaoJ.LinQ.Umifenovir treatment"/>
  <result pre="drug ArbidolProc. Natl. Acad. Sci. U.S.A.1142201720621428003465 114SchrezenmeierE.DÃ¶rnerT.Mechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatologyNat. Rev. Rheumatol.16202015516632034323 115DevauxC.A.RolainJ.M.ColsonP.RaoultD.New insights"/>
  <result pre="rheumatologyNat. Rev. Rheumatol.16202015516632034323 115DevauxC.A.RolainJ.M.ColsonP.RaoultD.New insights on the antiviral effects of" exact="chloroquine" post="against coronavirus: what to expect for COVID-19?Int. J. Antimicrob."/>
  <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
  <result pre="synthesis of a phosphoramidate prodrug of a pyrrolo [2, 1-f][triazin-4-amino]" exact="adenine" post="C-nucleoside (GS-5734) for the treatment of Ebola and emerging"/>
  <result pre="COVID-19? Not so fastJ.Â Biol. Regul. Homeost. Agents343202010.23812/20-EDITORIAL_1-5 146MehraM.R.DesaiS.S.RuschitzkaF.PatelA.N.Hydroxychloroquine or" exact="chloroquine" post="with or without a macrolide for treatment of COVID-19:"/>
  <result pre="for treatment of COVID-19: a multinational registry analysisLancet2020 147Funck-BrentanoC.SalemJ.E.Chloroquine or" exact="hydroxychloroquine" post="for COVID-19: why might they be hazardous?Lancet202010.1016/S0140-6736(20)31174-0 148MahaseE.Covid-19: 146"/>
  <result pre="might they be hazardous?Lancet202010.1016/S0140-6736(20)31174-0 148MahaseE.Covid-19: 146 researchers raise concerns over" exact="chloroquine" post="study that halted WHO trialBMJ369202010.1136/bmj.m2197 149GelerisJ.SunY.PlattJ.ZuckerJ.BaldwinM.HripcsakG.Observational study of hydroxychloroquine"/>
  <result pre="over chloroquine study that halted WHO trialBMJ369202010.1136/bmj.m2197 149GelerisJ.SunY.PlattJ.ZuckerJ.BaldwinM.HripcsakG.Observational study of" exact="hydroxychloroquine" post="in hospitalized patients with Covid-19N.Â Engl. J. Med.38220202411241832379955 Acknowledgements"/>
 </snippets>
</snippetsTree>
